Memorial Sloan Kettering Cancer Center Receives Record Gift of $150 Million from David Koch for Innovative Patient Care Facility
Memorial Sloan Kettering Cancer Center (MSK) announced that it has received the largest gift in its history, a commitment of $150 million from long-time MSK board member David H. Koch. This unprecedented contribution will transform cancer care with...
20-May-2015 8:05 AM EDT
Memorial Sloan Kettering Cancer Center “Specializes in You” with an Innovative and Personalized Digital Landscape
Memorial Sloan Kettering Cancer Center (MSK) introduced a new, consumer-friendly web presence for www.mskcc.org (Memorial Sloan Kettering Cancer Center) and www.sloankettering.edu (Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences,...
5-May-2015 2:15 PM EDT
Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising...
10-Apr-2015 9:05 AM EDT
Memorial Sloan Kettering Cancer Center (MSK) has debuted MyMSK, a new mobile application. The app, compatible with iPad, iPhone, and all iOS devices, allows MSK patients to quickly and easily access their lab and radiology results, view their...
23-Feb-2015 4:00 PM EST
In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration...
19-Feb-2015 11:00 AM EST
A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.
7-Dec-2014 12:30 PM EST
Studies Led by Memorial Sloan Kettering Investigators Show Immunotherapy Drugs Improve Outcomes in Hodgkin Lymphoma Patients
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already...
6-Dec-2014 1:00 PM EST
Positive Data from Pivotal Phase III Study Could Improve Standard of Care for Hodgkin Lymphoma Patients
In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.
6-Dec-2014 11:00 AM EST
2-Dec-2014 12:35 PM EST
9-Dec-2013 9:05 AM EST
3-Dec-2013 3:15 PM EST
20-Sep-2013 2:00 PM EDT
12-Mar-2013 6:00 PM EDT
28-Sep-2012 12:40 PM EDT